Zim Laboratories Ltd. (IN:ZIMLAB)
:ZIMLAB
Want to see IN:ZIMLAB full AI Analyst Report?
ZIMLAB Stock Chart & Stats
₹71.11
-₹1.76(-1.66%)
At close: 4:00 PM EST
₹71.11
-₹1.76(-1.66%)
Day’s Range― - ―
52-Week Range₹59.72 - ₹126.95
Previous CloseN/A
Volume52.11K
Average Volume (3M)6.28K
Market Cap
₹5.35B
Enterprise Value₹6.50B
Total Cash (Recent Filing)₹50.12M
Total Debt (Recent Filing)₹1.23B
Price to Earnings (P/E)20.0
Beta1.07
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.35
Shares Outstanding53,549,038
10 Day Avg. Volume5,950
30 Day Avg. Volume6,279
Financial Highlights & Ratios
PEG Ratio2.59
Price to Book (P/B)1.33
Price to Sales (P/S)3.78
P/FCF Ratio82.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet Equity GrowthRising equity over FY2025–FY2026 expands the company’s capital base and cushions leverage, improving financial flexibility. A stronger equity position supports longer-term investments, partnership negotiations and resilience to cyclical downturns without immediate reliance on external debt.
Positive Operating Cash FlowSustained positive operating cash flow implies underlying operations generate real cash, supporting day-to-day working capital and funding of core activities. If maintained, this cash generation reduces financing needs and underpins medium-term operational sustainability.
Differentiated Product & Diversified RevenueSpecialization in differentiated oral delivery formats plus multiple revenue channels (branded, exports, contract manufacturing, licensing) creates durable competitive advantages. Product differentiation and diverse streams reduce single-market dependency and aid long-term growth opportunities.
Bears Say
Negative And Volatile Free Cash FlowReturn to negative free cash flow in FY2026 signals weaker cash available after investments, reflecting working-capital swings or higher capex. Persistently negative FCF erodes the company’s ability to self-fund expansion, repay debt, or return capital, raising structural financing risk.
Weakening Profitability And MarginsA marked decline in net income and operating profit over the latest year indicates margin compression or higher costs. Reduced profitability lowers return on invested capital and may constrain reinvestment and pricing power if the trend persists, pressuring long-term earnings quality.
Inconsistent Revenue GrowthModest and uneven top-line trends undermine predictability of scale and make capacity planning harder. Inconsistent revenue, including prior declines, raises the risk that fixed costs and R&D investments will not be fully absorbed, limiting sustainable margin expansion over months.
Zim Laboratories Ltd. News
ZIMLAB FAQ
What was Zim Laboratories Ltd.’s price range in the past 12 months?
Zim Laboratories Ltd. lowest stock price was ₹59.72 and its highest was ₹126.95 in the past 12 months.
What is Zim Laboratories Ltd.’s market cap?
Zim Laboratories Ltd.’s market cap is ₹5.35B.
When is Zim Laboratories Ltd.’s upcoming earnings report date?
Zim Laboratories Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 78 days.
How were Zim Laboratories Ltd.’s earnings last quarter?
Zim Laboratories Ltd. released its earnings results on May 19, 2026. The company reported ₹0.76 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.76.
Is Zim Laboratories Ltd. overvalued?
According to Wall Street analysts Zim Laboratories Ltd.’s price is currently Overvalued.
Does Zim Laboratories Ltd. pay dividends?
Zim Laboratories Ltd. pays a Annually dividend of ₹0.167 which represents an annual dividend yield of N/A. See more information on Zim Laboratories Ltd. dividends here
What is Zim Laboratories Ltd.’s EPS estimate?
Zim Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zim Laboratories Ltd. have?
Zim Laboratories Ltd. has 53,549,038 shares outstanding.
What happened to Zim Laboratories Ltd.’s price movement after its last earnings report?
Zim Laboratories Ltd. reported an EPS of ₹0.76 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Zim Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:ZIMLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zim Laboratories Ltd.
ZIM Laboratories Limited develops, manufactures, and supplies pharmaceutical formulation and pre formulation ingredients in India and internationally. The company provides technology-based drug delivery solutions and non-infringing proprietary manufacturing processes for generic pharmaceutical products in semi-finished and finished categories/formulations, such as granules, pellets, taste masked powders, suspensions, tablets, capsules, and oral thin films. It serves therapeutic areas, such as urology, gastroenterology, cardiology, and anticoagulants, as well as antibiotics and anti-infectives, NSAIDs/pain analgesics, and vitamins and supplements. ZIM Laboratories Limited was incorporated in 1984 and is based in Nagpur, India.
Technical Analysis
Albert David Ltd
―
Lyka Labs Limited
―
Medicamen Biotech Limited
―
Nectar Lifesciences Ltd.
―
Venus Remedies Limited
―